Maria Heeter is an Activism and M&A Reporter at her current employer. She covers a diverse range of topics including business and economics, finance, investment, and the intersection of media and healthcare, with a particular focus on startups, AI, and market dynamics. Maria's work has been featured in prominent publications such as Ars Technica, The Information, and the Financial Times.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Maria Heeter's coverage mainly focuses on startups, technology, venture capital, and financial news. She frequently includes expert commentary and private sector announcements in her articles. If you have insights about the inner workings of startups or can provide analysis on investment trends within these industries, your expertise might be valuable to Maria.
She provides a comprehensive view of the business world with an emphasis on detailed analysis and insider perspectives. When reaching out to her, consider offering unique insights into industry trends or exclusive information from within companies that align with her coverage areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
US activist investor wants to split the conglomerate’s aerospace and automation businesses
By: Maria Heeter, Amelia Pollard
Fashion brand’s $8.5bn merger with Coach was scrapped after a months-long fight with antitrust regulators
By: Ian Johnston, Maria Heeter, Oliver Barnes
Experts forecast Trump administration could usher in new era of mergers and acquisitions among drugmakers
By: James Fontanella-Khan, Maria Heeter, Antoine Gara
US companies ink more than $35bn in transactions as election sends jolt of enthusiasm through industry
By: Antoine Gara, Maria Heeter
Potential deal highlights the mounting distress facing the retail pharmacy industry
By: Antoine Gara, Maria Heeter
Billionaire dealmaker Michael Rees sounds out potential partners to assemble new firm in mould of Blackstone
By: Ivan Levingston, Maria Heeter
Advisers see signs of ‘gangbuster year’ after rebound in deals pushes 2024 activity above $3tn
By: Oliver Barnes, James Fontanella-Khan, Maria Heeter
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers
By: Oliver Barnes, Maria Heeter
Deal would represent revival in activity after a slow year for biotech M&A
By: Amelia Pollard, Maria Heeter, James Fontanella-Khan, Oliver Barnes
Potential approach comes weeks after Biden blocked Nippon Steel’s proposed $15bn takeover
(833) 317-6278 
